[go: up one dir, main page]

PE20010629A1 - TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS - Google Patents

TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS

Info

Publication number
PE20010629A1
PE20010629A1 PE2000000903A PE0009032000A PE20010629A1 PE 20010629 A1 PE20010629 A1 PE 20010629A1 PE 2000000903 A PE2000000903 A PE 2000000903A PE 0009032000 A PE0009032000 A PE 0009032000A PE 20010629 A1 PE20010629 A1 PE 20010629A1
Authority
PE
Peru
Prior art keywords
pyridin
phenyl
derivatives
ilamine
triazol
Prior art date
Application number
PE2000000903A
Other languages
Spanish (es)
Inventor
Claus Riemer
Roland Jakob-Roetne
Gerda Huber Trottmann
Walter Hunkeler
Matthias Heinrich Nettekoven
Gavin John Kilpatrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010629A1 publication Critical patent/PE20010629A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE AMINO-TRIAZOLPIRIDINA DE FORMULA I, DONDE R1 ES HETEROARILO DE 5-6 MIEMBROS, (CH2)nOH, O(CH2)nFENILO, BENZOFURILO, INDOLILO, BENZOTIOFENILO, S-ALQUILO; R2 Y R4 SON H, CIANO, S(O)2-FENILO; R3 ES H, HALOGENO, HETEROARILO 5-6 MIEMBROS, FENILO, O-FENILO, ENTRE OTROS; R5 ES NR2, R2 ES H, ALQUILO, FENILO, BENCILO, ALQUILO, CO-ALCOXI, ALQUENILO, CO(CH2)nFENILO, ENTRE OTROS; n ES 0-4. SON COMPUESTOS PREFERIDOS 2-FURAN-2-IL-7-PIRIDIN-4-IL-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-5-ILAMINA, 2-FURAN-2-IL-7-PIRIDIN-3-IL-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-5-ILAMINA, 2-FURAN-2-IL-7-PIRIDIN-2-IL-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-5-ILAMINA, 7-(4-CLORO-FENIL)-2-(5-METIL-FURAN-2-IL)-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-5-ILAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS DERIVADOS DE AMINO-TRIAZOLPIRIDINA SON LIGANDOS RECEPTORES DE ADENOSINA Y PUEDEN SER UTILES EN LA REGULACION DEL METABOLISMO CELULAR, MODULACION DE ACTIVIDADES DEL SISTEMA NERVIOSO CENTRAL Y ENFERMEDADES COMO ALZHEIMER, PARKINSON, ESQUIZOFRENIAREFERS TO AMINO-TRIAZOLPYRIDINE DERIVATIVES OF FORMULA I, WHERE R1 IS 5-6 MEMBER HETEROARYL, (CH2) nOH, OR (CH2) nPHENYL, BENZOFURIL, INDOLYL, BENZOTHYL, S-ALKYL; R2 AND R4 ARE H, CYANE, S (O) 2-PHENYL; R3 IS H, HALOGEN, HETEROARYL 5-6 MEMBERS, PHENYL, O-PHENYL, AMONG OTHERS; R5 IS NR2, R2 IS H, ALKYL, PHENYL, BENZYL, ALKYL, CO-ALCOXY, ALKENYL, CO (CH2) nPHENYL, AMONG OTHERS; n IS 0-4. PREFERRED COMPOUNDS ARE 2-FURAN-2-IL-7-PYRIDIN-4-IL- [1,2,4] TRIAZOL [1,5-a] PYRIDIN-5-ILAMINE, 2-FURAN-2-IL-7- PYRIDIN-3-IL- [1,2,4] TRIAZOL [1,5-a] PYRIDIN-5-ILAMINE, 2-FURAN-2-IL-7-PYRIDIN-2-IL- [1,2,4] TRIAZOL [1,5-a] PYRIDIN-5-ILAMINE, 7- (4-CHLORO-PHENYL) -2- (5-METHYL-FURAN-2-IL) - [1,2,4] TRIAZOL [1,5 -a] PYRIDIN-5-ILAMINE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. AMINO-TRIAZOLPYRIDINE DERIVATIVES ARE ADENOSINE RECEPTORS AND MAY BE USEFUL IN THE REGULATION OF CELLULAR METABOLISM, MODULATION OF CENTRAL NERVOUS SYSTEM ACTIVITIES AND DISEASES SUCH AS ALZHEIMER, PARKINSONIA, SCHIZOFRENIA

PE2000000903A 1999-09-06 2000-09-04 TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS PE20010629A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99117578 1999-09-06

Publications (1)

Publication Number Publication Date
PE20010629A1 true PE20010629A1 (en) 2001-05-30

Family

ID=8238933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000903A PE20010629A1 (en) 1999-09-06 2000-09-04 TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS

Country Status (22)

Country Link
US (1) US6355653B1 (en)
EP (1) EP1214322A2 (en)
JP (1) JP2003528811A (en)
KR (1) KR20020027625A (en)
CN (1) CN1379777A (en)
AR (1) AR037484A1 (en)
AU (1) AU7511000A (en)
BR (1) BR0013792A (en)
CA (1) CA2383998A1 (en)
CZ (1) CZ20021220A3 (en)
HR (1) HRP20020172A2 (en)
HU (1) HUP0203316A3 (en)
IL (1) IL148167A0 (en)
MA (1) MA26816A1 (en)
MX (1) MXPA02001748A (en)
NO (1) NO20021077L (en)
PE (1) PE20010629A1 (en)
PL (1) PL354240A1 (en)
TR (1) TR200200579T2 (en)
WO (1) WO2001017999A2 (en)
YU (1) YU13502A (en)
ZA (1) ZA200201055B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506772B1 (en) * 2000-12-15 2003-01-14 Hoffmann-La Roche Inc. Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
RU2296763C2 (en) * 2001-10-08 2007-04-10 Ф.Хоффманн-Ля Рош Аг 8-amino-[1,2,4]triazolo-[1,5-a]pyridine-6-carboxylic acid amide and medicinal agent comprising thereof
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
WO2003063876A2 (en) 2002-01-28 2003-08-07 Kyowa Hakko Kogyo Co., Ltd. Methods of treating patients suffering from movement disorders
CA2489252A1 (en) * 2002-06-13 2003-12-24 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
EP1711498A2 (en) * 2004-01-26 2006-10-18 Altana Pharma AG 1,2,4-triazolo¬1,5-a|pyridines as gastric acid secretion inhibitors
JP2008524330A (en) 2004-12-21 2008-07-10 シェーリング コーポレイション Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonist
ES2273599B1 (en) 2005-10-14 2008-06-01 Universidad De Barcelona COMPOUNDS FOR THE TREATMENT OF HEADPHONE FIBRILATION.
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
EP2074084B1 (en) * 2006-09-25 2013-08-28 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2096923B1 (en) * 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
JP2010511018A (en) * 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
UA99610C2 (en) * 2007-04-10 2012-09-10 Х. Луннбэк А/С Heteroaryl amide analogues as p2x7 antagonists
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2704684A1 (en) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
PE20110063A1 (en) * 2008-06-20 2011-02-16 Genentech Inc DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS
CN102131389A (en) * 2008-06-20 2011-07-20 健泰科生物技术公司 Triazolopyridine JAK inhibitor compounds and methods
WO2010005782A1 (en) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
CN102164917A (en) * 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 Compounds which selectively modulate the CB2 receptor
MY153913A (en) * 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (en) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azetidine 2-carboxamide derivative that modulates CB2 receptor
EP2746282A1 (en) * 2009-07-17 2014-06-25 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
JP2013505295A (en) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compound that selectively modulates CB2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (en) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
EP2758396B1 (en) * 2011-09-19 2017-03-29 F. Hoffmann-La Roche AG Triazolopyridine compounds as pde10a inhibitors
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
TW201808906A (en) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 Substituted pyridine compounds as pesticides
CN106543175B (en) * 2016-10-28 2018-06-01 上海大学 Triaryl [1,2,4] triazole [1,5-a] pyridine derivate and preparation method thereof
JP7111733B2 (en) * 2017-03-16 2022-08-02 江蘇恒瑞医薬股▲ふん▼有限公司 Heteroaryl[4,3-c]pyrimidin-5-amine derivatives, methods for their preparation, and pharmaceutical uses thereof
MA52422A (en) 2018-02-27 2021-01-06 Incyte Corp IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
JP7391046B2 (en) 2018-05-18 2023-12-04 インサイト・コーポレイション Fused pyrimidine derivatives as A2A/A2B inhibitors
CN117304191A (en) 2018-07-05 2023-12-29 因赛特公司 Fused pyrazine derivatives as A2A/A2B inhibitors
JP7399589B2 (en) * 2018-09-12 2023-12-18 日本化薬株式会社 pest control agent
CN114787160B (en) 2018-12-20 2025-03-25 因赛特公司 Imidazopyridazines and imidazopyridines as inhibitors of activin receptor-like kinase-2
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
AU2022206418A1 (en) * 2021-01-09 2022-10-13 Bugworks Research, Inc. Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist
CN116082335A (en) * 2023-01-16 2023-05-09 上海凌凯医药科技有限公司 A kind of preparation method of diaryl ether compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
WO1999043678A1 (en) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease

Also Published As

Publication number Publication date
US6355653B1 (en) 2002-03-12
IL148167A0 (en) 2002-09-12
WO2001017999A3 (en) 2001-12-06
CZ20021220A3 (en) 2002-10-16
BR0013792A (en) 2002-05-14
AU7511000A (en) 2001-04-10
JP2003528811A (en) 2003-09-30
HUP0203316A3 (en) 2004-07-28
ZA200201055B (en) 2003-07-30
MXPA02001748A (en) 2002-08-06
NO20021077D0 (en) 2002-03-05
KR20020027625A (en) 2002-04-13
EP1214322A2 (en) 2002-06-19
TR200200579T2 (en) 2002-12-23
HUP0203316A2 (en) 2003-01-28
MA26816A1 (en) 2004-12-20
NO20021077L (en) 2002-03-05
CA2383998A1 (en) 2001-03-15
HRP20020172A2 (en) 2003-10-31
AR037484A1 (en) 2004-11-17
YU13502A (en) 2004-11-25
PL354240A1 (en) 2003-12-29
WO2001017999A2 (en) 2001-03-15
CN1379777A (en) 2002-11-13

Similar Documents

Publication Publication Date Title
PE20010629A1 (en) TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS
PE20020911A1 (en) INDOLE DERIVATIVES AS 5HT2 AGONISTS
PE59999A1 (en) DERIVATIVES OF 1,3,8-TRIAZA-ESPIRO [4,5] DECAN-4-ONA-8-SUBSTITUTED
PE20030415A1 (en) POLYCYCLICAL DERIVATIVES OF GUANINE AS INHIBITORS OF PHOSPHODIESTERASE V
PE20040168A1 (en) PYRROLOPYRIDAZINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
PE20030129A1 (en) IMIDAZOTRIAZINES
PE20020470A1 (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF ENZYMES PROTEIN KINASES
UY28150A1 (en) THERAPEUTIC AGENTS
PE20010401A1 (en) DERIVATIVES OF 8-PHENYL-6,9-DIHYDRO- [1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA AS INHIBITORS OF CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE
PE20000337A1 (en) PYRAZOLPYRIMIDINES AND PYRAZOLTRIAZINES
PE20050896A1 (en) QUINOLINE INTERMEDIARIES AS INHIBITORS OF TIROSINE KINASES OF RECEPTORS AND THE SYNTHESIS OF THE SAME
PE20020720A1 (en) BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LINKS FOR GABAA RECEPTORS
PE20040512A1 (en) PYRAZOLE-PYRIMIDINE ANILINE COMPOUND
PE91198A1 (en) DERIVATIVES PIRIDO [3,4-d] PIRIMIDINA
PE20010854A1 (en) USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS
PE20040590A1 (en) COMPOSITIONS OF PYRROLOTRIAZINE ANILINE AS KINASE INHIBITORS
PE20030292A1 (en) FUSED BICYCLE HETEROARYL COMPOUNDS REPLACED WITH HETEROARYL AS GABAA RECEIVER LINKS
PE20090718A1 (en) SPIROINDOLINONE DERIVATIVES
PE20040934A1 (en) PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF TYROSINE KINASES
PE20020298A1 (en) DERIVATIVES OF 1,3,8-TRIAZA-SPIRO [4,5] DECAN-4-ONA AS ANTAGONISTS OF NEUROQUININ NK-1 RECEPTORS
AR023727A1 (en) COMPOUNDS USED IN THE TREATMENT OF INFLAMMATORY MATTERS
IL156779A0 (en) Purine derivatives as purinergic receptor antagonists
PE20100741A1 (en) COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
PE20021072A1 (en) DERIVATIVES OF DIHYDRO-BENZO (b) (1,4) -DIAZEPIN-2-ONA AS ANTAGONISTS I OF mGLUR2
PE20050141A1 (en) DERIVATIVES OF 2-ALKINYL-AND 2-ALKENYL-PIRAZOLO- [4,3-e] -1,2,4-TRIAZOLO- [1,5-c] -PYRIDINE AS ANTAGONISTS OF THE A2a ADENOSINE RECEPTOR

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed